This year, Dr. Wheldon’s research was featured at the International Anal Neoplasia Society (IANS) 2026 Scientific Meeting in Syndey Australia. While Dr. Wheldon could not be there in person, his abstract titled “Provider Willingness to Implement High-Resolution Anoscopy: Key Determinants Across Clinical Specialty” was featured as a virtual poster. The meeting theme, “Taking It to the People,” fit our research well. It asked a practical question: if we want anal cancer screening to reach the people who need it, what will it take to get more clinicians to offer it?
Why this matters
Anal cancer is preventable. Like cervical cancer, most cases are caused by HPV and develop slowly from precancerous changes that can be found and treated. Some groups face much higher risk, including people living with HIV, gay and bisexual men, and women with a history of HPV-related gynecologic cancers.
The key screening tool is high-resolution anoscopy (HRA), a magnified exam that lets a clinician find and treat precancerous lesions before they become cancer. The evidence that this works is strong, and national screening guidelines now exist. The problem is that very few clinicians are trained to perform HRA. Patients can wait months for an appointment or travel long distances to reach one, and that shortage falls hardest on the communities with the highest risk.
What we did
Between July and September 2025, we surveyed 87 U.S. clinicians who do not currently perform HRA, drawn from four specialties that could plausibly expand access:
- Colorectal surgery (20)
- OB/GYN (26)
- Gastroenterology (21)
- Infectious diseases (20)
The survey was guided by Normalization Process Theory, a framework for understanding what it takes for a new practice to become a routine part of clinical care. In plain terms, it asks whether clinicians understand the practice, believe it is legitimate and worth doing, think it fits their workflow, and see it paying off.
What we found
Awareness is low. Only about one in three clinicians (32%) knew that anal cancer screening guidelines exist. Nearly half (48%) said they were not aware, and another 20% weren’t sure.
Access is limited. HRA was available in only 31% of respondents’ practices or organizations. Infectious disease clinicians reported the most access (50%), while colorectal surgery, OB/GYN, and gastroenterology were all under 30%.
Willingness is there. Clinicians were moderately to highly willing to get involved, averaging 3.59 on a 5-point scale. They were most open to completing HRA training themselves and somewhat less ready to take the bigger step of consulting an expert to start an HRA clinic.
Confidence lags behind. Self-efficacy, meaning clinicians’ confidence in their own ability to do this, was the lowest-rated factor we measured.
Beliefs and support drive willingness, not specialty. Our statistical model explained about 64% of the differences in clinicians’ willingness. The two strongest predictors were (1) believing that HRA has value and fits into clinical practice and (2) having concrete support and facilitators in place, such as training opportunities. Specialty, age, and guideline awareness did not independently predict willingness.
When we asked clinicians what stands in the way, their answers fell into five themes: scope of practice, time and workflow, cost and reimbursement, infrastructure, and patient factors.
What it means
The takeaway is encouraging. Many clinicians are open to adding HRA to their practice. What holds them back is less about a lack of interest and more about legitimacy and confidence: whether HRA feels like “their job,” whether it fits their clinic, and whether they feel able to do it well. That gap is widest among specialists who don’t routinely see anal health concerns or care for the highest-risk patient populations.
That points to clear strategies for expanding the HRA workforce:
- Make the case for why HRA belongs in each specialty’s scope of practice.
- Build practical supports such as protected training time, mentorship, and clinic infrastructure.
- Address reimbursement so that offering HRA is sustainable.
This study is part of the CHEER Lab’s broader work on improving the use of cancer prevention and screening services and reducing cancer disparities in LGBTQ+ communities. Closing the HRA workforce gap is an essential step toward making anal cancer prevention available to everyone who needs it.
This research was supported by the TUFCCC/HC Regional Comprehensive Cancer Health Disparity Partnership (NCI/NIH U54 CA221704). The contents are the authors’ responsibility and do not necessarily represent the official views of NCI or NIH. Questions? Contact Dr. Wheldon at chris.wheldon@temple.edu.